Fund Evaluator:
Janus Henderson Global Life Sciences D (JNGLX)
Follow This Fund
Best Performing in Health Over the Last Year
| 77.3% | Fidelity Advisor Biotechnology Z (FIJYX) |
| 77.1% | Fidelity Advisor Biotechnology I (FBTIX) |
| 71.4% | Eventide Healthcare & Life Sciences N (ETNHX) |
| 71.0% | Fidelity Select Biotechnology (FBIOX) |
| 58.4% | Rydex Biotechnology Inv (RYOIX) |
Fund Details
Janus Henderson Global Life Sciences D Overview
Janus Henderson Global Life Sciences D (JNGLX) is an actively managed Sector Equity Health fund. Janus Henderson launched the fund in 1998.
The investment seeks long-term growth of capital. The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio management believes have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector.
About Janus Henderson Global Life Sciences D (JNGLX)
There are 2 members of the management team with an average tenure of 11.30 years: Daniel Lyons (2023), Andy Acker (2007). Management tenure is more important for actively managed funds than passive index funds.
The fund has 2 primary benchmarks: MSCI World NR USD index with a weighting of 100% and S&P 500 (TR) (1970) index with a weighting of 100%. Janus Henderson Global Life Sciences D has 100 securities in its portfolio. The top 10 holdings constitute 41.4% of the fund’s assets. The fund meets the SEC requirement of being classified as a diversified fund. The fund is not considered to have an ESG focus with its investment selection and management.
Janus Henderson Global Life Sciences D is part of the Equity global asset class and is within the Sector Equity fund group. Janus Henderson Global Life Sciences D has 13.8% of its portfolio invested in foreign issues. The overall assets allocated to domestic stock is 85.2%. There is 13.8% allocated to foreign stock, and 0.3% is allocated to preferred stocks. The bond allocation as a percentage of total assets is 0.0% (0.0% domestic bond, 0.0% foreign bond and 0.0% convertible bond). Janus Henderson Global Life Sciences D has 0.3% of the portfolio in cash.
Assets Under Management
The fund has $1 billion in total assets, which is above the $869 million average for the Health category. Normally, lower assets under management translates to higher average expense ratios, and greater total assets are desired. However, for some investment categories, such as small-cap investing, it may be difficult for the manager to fully employ the desired active strategy if assets grow too large or too quickly.
JNGLX Performance and Fees
The expense ratio measures how much of a fund’s assets are used for administrative expenses and operating expenses, including adviser fees and fees for the transfer agent and custodial services. The Janus Henderson Global Life Sciences D expense ratio is high compared to funds in the Health category. Janus Henderson Global Life Sciences D has an expense ratio of 0.81%, which is 33% lower than its category average, making the fund expense ratio grade a B. While it is difficult to predict returns, it is known that high annual expense ratios reduce your rate of return, and excessive fees are difficult to overcome. Active management normally comes with higher expense ratios than passive index management. Certain investment categories such as small company and foreign also normally have higher expense ratios. It is best to compare fund expense ratios against the category averages for meaningful assessments.
High portfolio turnover can translate to higher expenses and lower aftertax returns. Janus Henderson Global Life Sciences D has a portfolio turnover rate of 30%, indicating that holds its assets around 0.0 years. By way of comparison, the average portfolio turnover is 61% for the Health category.
Recently, in the month of June 2026, Janus Henderson Global Life Sciences D returned 8.2%, which earned it a grade of B, as the Health category had an average return of 8.4%. The letter grades of A, B, C, D and F are based upon relative rankings within the investment category. A grade of A, for example, would indicate that the return is in the highest 20% for that time period compared to all funds in that category.
Janus Henderson Global Life Sciences D has a trailing yield of 0.40%, which is above the 0.39% category average. The fund normally distributes its income annually and its capital gains annually.
It’s natural to seek the best-performing investments, but you must consider the relationship between risk and return and the impact of costs and taxes on your realized returns.
Janus Henderson Global Life Sciences D Grades
Year to date, the fund has returned 8.6%, 1.1 percentage points better than the category, which translates into a grade of B. The fund has returned 39.5% over the past year (grade of B), 13.5% over the past three years (grade of B) and 8.5% per year over the past five years (grade of A) and 12.1% per year over the past 10 years (grade of A).
For more mutual fund grades, analysis and screening tools to help your investment discovery, join AAII for a $2, full-access trial. Learn more here: https://invest.aaii.com/membership.
Otherwise, for more information about Janus Henderson Global Life Sciences D, including its riskiness, submit your email to unlock the rest of the article.
Gain access to exclusive AAII member-only content.
JNGLX Trailing NAV Total Returns Data as of 6/30/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| JNGLX Return (NAV) | 8.2% | 12.8% | 39.5% | 13.5% | 8.5% | 12.1% |
| JNGLX Grade | B | B | B | B | A | A |
| +/- Category | -0.3% | 0.9% | 5.9% | 2.5% | 3.3% | 2.0% |
| Health Avg | 8.4% | 11.9% | 33.6% | 11.0% | 5.2% | 10.0% |
| JNGLX Tax Cost Ratio | na | na | 1.1% | 1.3% | 1.3% | 1.4% |
JNGLX Annual NAV Total ReturnsData as of 6/30/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| JNGLX Return (NAV) | 8.6% | 24.8% | 3.6% | 7.5% | -2.7% | 6.8% | 25.6% | 29.2% | 4.3% | 22.6% | -12.3% |
| JNGLX Grade | B | B | C | B | A | D | B | C | B | C | D |
| +/- Category | 1.1% | 4.2% | 1.1% | 1.9% | 6.7% | -1.9% | 1.1% | 0.8% | 4.0% | -0.8% | -1.4% |
| Health Avg | 7.5% | 20.6% | 2.5% | 5.6% | -9.4% | 8.7% | 24.5% | 28.4% | 0.4% | 23.4% | -10.9% |
| Risk Measures | |
| Standard Deviation: | 15.7% |
| Total Risk Index: | 1.29 - Above Average |
| Category Risk Index: | 0.98 - Above Average |
| Category Risk Grade: | D (70% Rank) |
| Beta: | 0.66 |
| R-Squared: | 29% |
| Leveraged Fund: | No |
| Inverse Fund: | No |
| Portfolio Characteristics | |
| Equity Investment Style: | Large-Cap Blend |
| Bond Investment Style: | na |
| Yield: | 0.4% |
| Dividend Distribution: | Annually |
| Cap Gains Distribution: | Annually |
| Total Assets: | $5395 Mil |
| Fund Total Assets: | $1,814 Mil |
| Share Class Type: | D |
| Portfolio Turnover: | 30% |
Management Team
| Number of Managers: 2 | |||
| Longest Tenure: 19.2 years | |||
| Average Tenure: 11.3 years | |||
| Managers (Year): Acker Andy (2007), Lyons Daniel (2023) | |||
Portfolio Composition (as of 4/30/26)
| # of Holdings: | 100 |
| % in Top 10 Holdings: | 41.4% |
| Fund is Non-Diversified: | No |
| % in Foreign Issues: | 13.8% |
Portfolio Allocation |
|
| Domestic Stock: | 85.2% |
| Foreign Stock: | 13.8% |
| Preferred Stock: | 0.3% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | 0.4% |
| Cash: | 0.3% |
Purchase Information
| Fund Family: | Janus Henderson |
| Phone Number: | 800-525-3713 |
| Website: | www.janushenderson.com |
| Status: | Closed |
| Inception Date: | December 31, 1998 |
| Min. Initial Purchase: | $2,500 |
| Min. Initial IRA Purchase: | $1,000 |
| True No-Load: | Yes |
| Front Load Maximum: | 0.00% |
| Deferred Charge Maximum: | 0.00% |
| Redemption Charge Maximum: | 0.00% |
| 12b-1 Fee: | na |
Expenses and Fees | |
| Expense Ratio (%): | 0.81% ( Rating : High ) |
| Category Average Expense Ratio (%): | 1.21% |
| Share Class: | Janus Henderson Global Life Sciences D |
| Min. Subsequent Purchase: | $ 50 |
| Min. Subsequent IRA Purchase: | $ 50 |
